Evaxion Biotech

Evaxion develops personalized and precision vaccines and immunotherapies for cancer and infectious diseases using its proprietary AI platform, AI-Immunology. The platform combines in-house AI building blocks into tailored prediction models that decode the human immune system, enabling rapid target discovery and drug design within twenty-four hours. The company operates through a multi-partner business model, engaging in target discovery, drug design, and development agreements, and has been listed on the Nasdaq Capital Market exchange under the ticker EVAX since 2021.